Abstract:The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) update 3 recommends that histologic grade II and III IDH-wildtype diffuse astrocytic gliomas that harbor EGFR amplification, the combination of whole chromosome 7 gain and whole chromosome 10 loss (7 + /10 −), or TERT promoter (pTERT) mutations should be considered as glioblastomas (GBM), World Health Organization grade IV. In this retrospective study, we examined the utility of molecular classification based on pTERT status and copy-number alterations (CNAs) in IDH-wildtype lower grade gliomas (LGGs, grade II, and III). The impact on survival was evaluated for the pTERT mutation and CNAs, including EGFR gain/amplification, PTEN loss, CDKN2A homozygous deletion, and PDGFRA gain/amplification. We analyzed 46 patients with IDH-wildtype/pTERT-mutant (mut) LGGs and 85 with IDH-wildtype/pTERT-wildtype LGGs. EGFR amplification and a combination of EGFR gain and PTEN loss (EGFR + /PTEN −) were significantly more frequent in pTERT-mut patients (p < 0.0001). Cox regression analysis showed that the pTERT mutation was a significant predictor of poor prognosis (hazard ratio [HR] 2.79, 95% confidence interval [CI] 1.55–4.89, p = 0.0008), but neither EGFR amplification nor EGFR + /PTEN − was an independent prognostic factor in IDH-wildtype LGGs. PDGFRA gain/amplification was a significant poor prognostic factor in IDH-wildtype/pTERT-wildtype LGGs (HR 2.44, 95% CI 1.09–5.27, p = 0.03, Cox regression analysis). The IDH-wildtype LGGs with either pTERT-mut or PDGFRA amplification were mostly clustered with GBM by DNA methylation analysis. Thus, our study suggests that analysis of pTERT mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic gliomas with molecular features of glioblastoma. The PDGFRA status may help further delineate IDH-wildtype/pTERT-wildtype LGGs. Methylation profiling showed that IDH-wildtype LGGs without molecular features of GBM were a heterogeneous group of tumors. Some of them did not fall into existing categories and had significantly better prognoses than those clustered with GBM.

PATH-37. PROGNOSTIC ROLE OF TERT PROMOTER MUTATIONS IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations

TERT Promoter Mutations Contribute to Subset Prognostication of Lower-Grade Gliomas

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas

TERT Promoter Mutations Contribute to IDH Mutations in Predicting Differential Responses to Adjuvant Therapies in WHO Grade II and III Diffuse Gliomas.

The place and prognostic value of tert promoter mutation in molecular classification in grade ii-iii glial tumors and primary glioblastomas

[Prognostic Significance of Combined TERT and IDH Gene Mutation Analysis in Diffusely Infiltrating Gliomas].

Classification Based on Mutations of TERT Promoter and IDH Characterizes Subtypes in Grade II/III Gliomas.

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

Paradoxical Prognostic Impact of TERT Promoter Mutations in Gliomas Depends on Different Histological and Genetic Backgrounds.

Prognostic stratification of patients with primary glioblastoma based on mutations of TERT promoter and IDH1

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma

Molecular landscape of <scp> <i>IDH</i> </scp> ‐wild type, <scp> p <i>TERT</i> </scp> ‐wild type adult glioblastomas

Molecular landscape of IDH‐wild type, pTERT‐wild type adult glioblastomas

PATH-34. H3F3A AND TERT PROMOTER MUTATIONS ARE POOR PROGNOSTICATORS IN PEDIATRIC LOW-GRADE GLIOMAS

TERT Promoter Mutated WHO Grades II and III Gliomas Are Located Preferentially in the Frontal Lobe and Avoid the Midline.

The TERT Promoter Mutation Status and MGMT Promoter Methylation Status, Combined with Dichotomized MRI‐derived and Clinical Features, Predict Adult Primary Glioblastoma Survival

Correlation between IDH, ATRX, and TERT promoter mutations in glioma

TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas